Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MDXG NASDAQ:NVCR NASDAQ:PLSE NASDAQ:PRCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMDXGMiMedx Group$3.60$3.62$3.03▼$7.99$536.22M1.481.25 million shs947,120 shsNVCRNovoCure$17.78$15.03$9.82▼$18.92$2.06B0.931.36 million shs1.04 million shsPLSEPulse Biosciences$24.37$23.12$12.56▼$28.53$1.69B1.65297,167 shs403,318 shsPRCTPROCEPT BioRobotics$25.700.0%$25.84$19.35▼$62.17$1.46B0.851.20 million shs1.38 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMDXGMiMedx Group0.00%-3.74%+1.12%-18.37%-40.40%NVCRNovoCure0.00%+3.61%+1.14%+43.62%+1.31%PLSEPulse Biosciences0.00%-3.79%-0.73%+11.64%+54.53%PRCTPROCEPT BioRobotics0.00%-7.65%-1.61%-8.18%-57.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMDXGMiMedx Group$3.60$3.62$3.03▼$7.99$536.22M1.481.25 million shs947,120 shsNVCRNovoCure$17.78$15.03$9.82▼$18.92$2.06B0.931.36 million shs1.04 million shsPLSEPulse Biosciences$24.37$23.12$12.56▼$28.53$1.69B1.65297,167 shs403,318 shsPRCTPROCEPT BioRobotics$25.700.0%$25.84$19.35▼$62.17$1.46B0.851.20 million shs1.38 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMDXGMiMedx Group0.00%-3.74%+1.12%-18.37%-40.40%NVCRNovoCure0.00%+3.61%+1.14%+43.62%+1.31%PLSEPulse Biosciences0.00%-3.79%-0.73%+11.64%+54.53%PRCTPROCEPT BioRobotics0.00%-7.65%-1.61%-8.18%-57.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMDXGMiMedx Group 2.71Moderate Buy$8.50136.11% UpsideNVCRNovoCure 2.38Hold$27.2953.46% UpsidePLSEPulse Biosciences 2.50Moderate Buy$30.6725.84% UpsidePRCTPROCEPT BioRobotics 2.36Hold$41.3660.95% UpsideCurrent Analyst Ratings BreakdownLatest MDXG, NVCR, PLSE, and PRCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026PRCTPROCEPT BioRobotics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$31.00 ➝ $29.006/4/2026PLSEPulse Biosciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$32.006/1/2026NVCRNovoCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026MDXGMiMedx Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/4/2026MDXGMiMedx Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/4/2026NVCRNovoCure Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$13.50 ➝ $17.005/1/2026NVCRNovoCure EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/30/2026PRCTPROCEPT BioRobotics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$28.00 ➝ $35.004/30/2026MDXGMiMedx Group Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$7.00 ➝ $6.004/21/2026NVCRNovoCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026PLSEPulse Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMDXGMiMedx Group$418.63M1.28$0.55 per share6.50$1.73 per share2.08NVCRNovoCure$655.35M3.14N/AN/A$3.04 per share5.85PLSEPulse Biosciences$350K4,818.99N/AN/A$1.19 per share20.48PRCTPROCEPT BioRobotics$308.05M4.75N/AN/A$6.55 per share3.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMDXGMiMedx Group$48.58M$0.2018.0060.00N/A7.88%21.03%15.92%7/29/2026 (Estimated)NVCRNovoCure-$136.23M-$1.53N/AN/AN/A-25.66%-50.82%-16.48%7/23/2026 (Estimated)PLSEPulse Biosciences-$72.78M-$1.10N/AN/AN/AN/A-86.67%-73.61%8/11/2026 (Estimated)PRCTPROCEPT BioRobotics-$95.57M-$1.82N/AN/AN/A-31.82%-27.70%-20.29%8/5/2026 (Estimated)Latest MDXG, NVCR, PLSE, and PRCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/4/2026Q1 2026PLSEPulse Biosciences-$0.32-$0.27+$0.05-$0.27$0.25 million$0.40 million4/30/2026Q1 2026NVCRNovoCure-$0.5122-$0.62-$0.1078-$0.62$167.77 million$174.06 million4/29/2026Q1 2026MDXGMiMedx Group-$0.07-$0.05+$0.02-$0.07$65.80 million$58.99 million4/29/2026Q1 2026PRCTPROCEPT BioRobotics-$0.55-$0.56-$0.01-$0.56$80.52 million$83.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMDXGMiMedx GroupN/AN/AN/AN/AN/ANVCRNovoCureN/AN/AN/AN/AN/APLSEPulse BiosciencesN/AN/AN/AN/AN/APRCTPROCEPT BioRoboticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMDXGMiMedx Group0.075.394.81NVCRNovoCure0.712.902.70PLSEPulse BiosciencesN/A7.267.24PRCTPROCEPT BioRobotics0.156.735.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMDXGMiMedx Group79.15%NVCRNovoCure84.61%PLSEPulse Biosciences76.95%PRCTPROCEPT BioRobotics89.46%Insider OwnershipCompanyInsider OwnershipMDXGMiMedx Group2.50%NVCRNovoCure5.52%PLSEPulse Biosciences74.00%PRCTPROCEPT BioRobotics17.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMDXGMiMedx Group870148.95 million145.22 millionOptionableNVCRNovoCure1,605115.82 million109.43 millionOptionablePLSEPulse Biosciences14069.21 million18.00 millionOptionablePRCTPROCEPT BioRobotics43056.92 million47.02 millionOptionableMDXG, NVCR, PLSE, and PRCT HeadlinesRecent News About These CompaniesBiondo Investment Advisors LLC Reduces Stock Position in PROCEPT BioRobotics Corporation $PRCTJune 14 at 3:52 AM | marketbeat.comRhenman & Partners Asset Management AB Boosts Stock Position in PROCEPT BioRobotics Corporation $PRCTJune 13 at 5:48 AM | marketbeat.comProcept BioRobotics shares slide after Leerink downgrade cites rising competitive risksJune 12 at 9:10 AM | msn.comPROCEPT BioRobotics (NASDAQ:PRCT) Trading Down 8.6% on Analyst DowngradeJune 11, 2026 | marketbeat.comPROCEPT BioRobotics (NASDAQ:PRCT) Rating Lowered to Market Perform at Leerink PartnersJune 11, 2026 | marketbeat.comPROCEPT BioRobotics (NASDAQ:PRCT) EVP Sells $10,167.36 in StockJune 11, 2026 | insidertrades.comPROCEPT BioRobotics Shareholders Back Board, Pay and AuditorJune 10, 2026 | tipranks.comFiera Capital Corp Boosts Holdings in PROCEPT BioRobotics Corporation $PRCTJune 9, 2026 | marketbeat.comBTIG Sticks to Its Hold Rating for PROCEPT BioRobotics (PRCT)June 6, 2026 | theglobeandmail.comPROCEPT BioRobotics (PRCT) Receives a Buy from TD CowenJune 2, 2026 | theglobeandmail.comPROCEPT BioRobotics (PRCT) Is Down 9.2% After Aquablation WATER IV Milestones - What's ChangedJune 1, 2026 | finance.yahoo.comProcept Biorobotics wins expanded FDA IDE for Aquablation, completes study enrollmentMay 28, 2026 | massdevice.comPROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE ApprovalMay 28, 2026 | globenewswire.comHere’s What the Street Thinks About PROCEPT BioRobotics Corporation (PRCT)May 26, 2026 | finance.yahoo.comLisanti Capital Growth LLC Buys Shares of 35,890 PROCEPT BioRobotics Corporation $PRCTMay 24, 2026 | marketbeat.comDNB Asset Management AS Has $3.13 Million Stock Position in PROCEPT BioRobotics Corporation $PRCTMay 20, 2026 | marketbeat.com5 Robotics Stocks to Watch as Physical AI Builds Momentum (PRCT)...May 18, 2026 | marketbeat.comPROCEPT BioRobotics Corporation (NASDAQ:PRCT) Receives Average Recommendation of "Hold" from BrokeragesMay 18, 2026 | marketbeat.comPinnacle Associates Ltd. Takes Position in PROCEPT BioRobotics Corporation $PRCTMay 16, 2026 | marketbeat.comAUA Guidelines Strengthen Recommendation for Aquablation® TherapyMay 14, 2026 | globenewswire.comQ1 Results Say a Lot About Procept Biorobotics Corp (PRCT) Stock OutlookMay 12, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDXG, NVCR, PLSE, and PRCT Company DescriptionsMiMedx Group NASDAQ:MDXG$3.60 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$3.60 0.00 (0.00%) As of 06/12/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.NovoCure NASDAQ:NVCR$17.78 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$17.76 -0.02 (-0.08%) As of 06/12/2026 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Pulse Biosciences NASDAQ:PLSE$24.37 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$23.71 -0.66 (-2.71%) As of 06/12/2026 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.PROCEPT BioRobotics NASDAQ:PRCT$25.70 -0.01 (-0.04%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$25.70 0.00 (-0.01%) As of 06/12/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Viasat's Orbiting Profits: Space Force Jackpot? What to Expect From Q2 Earnings as Tech Strength Broadens ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
